Becton Dickinson and Co (NYSE:BDX) – Equities research analysts at Leerink Swann reduced their Q2 2018 earnings per share (EPS) estimates for Becton Dickinson and in a report issued on Tuesday. Leerink Swann analyst R. Newitter now forecasts that the medical instruments supplier will earn $2.65 per share for the quarter, down from their previous forecast of $2.71.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping the consensus estimate of $2.41 by $0.07. The company had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm posted $2.33 earnings per share.

Several other research firms have also recently weighed in on BDX. Bank of America restated a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a report on Friday, January 19th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price target on the stock in a report on Friday, January 19th. Piper Jaffray Companies restated an “overweight” rating and set a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday. Morgan Stanley boosted their price target on shares of Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a report on Wednesday. Finally, Stifel Nicolaus restated a “buy” rating and set a $245.00 price target on shares of Becton Dickinson and in a report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $237.27.

Becton Dickinson and (BDX) traded up $1.30 during trading hours on Friday, hitting $212.74. 233,417 shares of the stock traded hands, compared to its average volume of 1,598,049. The company has a current ratio of 1.54, a quick ratio of 5.03 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $59,084.54, a P/E ratio of 161.40, a PEG ratio of 1.58 and a beta of 1.12. Becton Dickinson and has a one year low of $175.66 and a one year high of $248.39.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pathstone Family Office LLC boosted its stake in Becton Dickinson and by 0.4% in the second quarter. Pathstone Family Office LLC now owns 3,974 shares of the medical instruments supplier’s stock valued at $2,530,000 after acquiring an additional 15 shares during the last quarter. Sii Investments Inc. WI boosted its stake in Becton Dickinson and by 2.2% in the second quarter. Sii Investments Inc. WI now owns 1,738 shares of the medical instruments supplier’s stock valued at $342,000 after acquiring an additional 38 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in Becton Dickinson and by 0.5% in the second quarter. Quadrant Capital Group LLC now owns 9,960 shares of the medical instruments supplier’s stock valued at $1,925,000 after acquiring an additional 45 shares during the last quarter. WFG Advisors LP boosted its stake in Becton Dickinson and by 0.9% in the second quarter. WFG Advisors LP now owns 5,376 shares of the medical instruments supplier’s stock valued at $1,049,000 after acquiring an additional 48 shares during the last quarter. Finally, Aureus Asset Management LLC boosted its stake in Becton Dickinson and by 5.6% in the second quarter. Aureus Asset Management LLC now owns 1,695 shares of the medical instruments supplier’s stock valued at $331,000 after acquiring an additional 90 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.41%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s payout ratio is 229.01%.

COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/q2-2018-earnings-forecast-for-becton-dickinson-and-co-issued-by-leerink-swann-bdx/1854749.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.